GLP-1

CMS launches Medicare GLP-1 Bridge program July 2026, offering Novo Nordisk's Wegovy at $50 monthly copay. Amazon Pharmacy expands oral Ozempic access.

Novo Nordisk reported Q1 2026 adjusted operating profit of DKK 32.9B, raising 2026 guidance on Wegovy® pill's success with 2M total prescriptions since January launch.

Eli Lilly beat Q1 earnings expectations and raised full-year guidance, driven by blockbuster demand for weight-loss drugs Mounjaro and Zepbound.

West Pharmaceutical beats Q1 earnings with 21% sales growth driven by GLP-1 demand, raises full-year guidance, and launches $1B share repurchase program.

DexCom benefits from GLP-1 weight-loss drug adoption regardless of pharmaceutical winner, leveraging competitive moats in CGM technology and ecosystem integration.

Kailera Therapeutics raised $625M in largest biotech IPO since 2021, entering competitive obesity market with oral GLP-1 candidate showing 12.1% weight loss.

Eli Lilly bets on AI-driven drug discovery alongside its $11B weight loss drug franchise, partnering with Nvidia and Insilico Medicine to build next-generation blockbusters.

Regeneron's 35% recovery masks limited multimillionaire potential at $79B valuation, positioning shares for S&P-matching returns rather than exceptional gains.

Novo Nordisk and United Biotechnology's experimental drug UBT251 outperformed semaglutide in phase 2 trials, delivering stronger weight loss and glucose control.

Eli Lilly ($LLY) outpaces Vertex ($VERX) as superior growth stock pick with Zepbound dominance in booming weight-loss market and stronger financials at comparable valuations.

Novo Nordisk leads GLP-1 market but faces Eli Lilly competition; Amgen's MariTide offers differentiated approach with less portfolio risk.

Roche's obesity drug petrelintide achieved 10.7% weight loss in Phase 2 trials but significantly trails GLP-1 rivals Novo Nordisk and Eli Lilly, triggering sharp stock declines.

Pfizer's 6.4% dividend yield attracts income investors, but structural challenges like patent expirations and a payout ratio exceeding 100% present execution risks.

Novo Nordisk's obesity drug UBT251 achieved 19.7% weight loss in Phase 2 trials for Chinese patients, offsetting recent setbacks from a failed competitor drug trial.

Novo Nordisk's stock fell 16% after CagriSema obesity drug failed to match Eli Lilly's tirzepatide in trial, showing weaker weight loss results and jeopardizing approval timeline.

Viking Therapeutics poised for growth as obesity drug market expands to $100 billion by decade's end. VK2735's Phase 3 success could establish the company as a key competitor.